AI unit, has placed strict controls over the release of its research papers to maintain its competitive edge in ...
Isomorphic Labs, which uses artificial intelligence technologies for drug discovery, has raised $600 million in its first ...
The London-based business – which launched in 2021 – will use the funds to further its research, expand its team and continue ...
Isomorphic Labs, the AI drug-discovery platform that was spun out of Google's DeepMind in 2021, has raised external capital for the first time. The $600 ...
Isomorphic Labs, an Alphabet-backed AI biotech firm, raised $600M to boost its AI drug design engine, expand clinical ...
Though the paper does discuss AGI through what Google DeepMind is doing, it notes that no single organization should tackle ...
Isomorphic Labs says it is advancing drug design programs across multiple therapeutic areas and drug modalities. These ...
Alphabet created Isomorphic Labs in 2021, spinning it out from DeepMind, the AI startup it acquired in 2014. DeepMind’s ...
AlphaFold 3, the improved version of the model used by Isomorphic Labs’ drug design engine, debuted last May. It can predict ...
Alphabet’s Gemini 2.5 Pro sets new AI benchmarks, powered by DeepMind and custom TPUs. Learn why GOOG stock offers long-term ...
Isomorphic Labs, the AI drug-discovery platform that was spun out of Google’s DeepMind in 2021 ... participation from GV and existing investor Alphabet, Google’s parent, it said.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results